Intellia Therapeutics' stock surged 5.96% in pre-market trading on Thursday, following the release of its fourth quarter and full-year 2025 financial results.

The biotech company reported quarterly earnings that significantly exceeded analyst expectations. Intellia posted a loss of $0.83 per share, beating the consensus estimate of a $0.96 loss by 13.72%. More impressively, the company reported quarterly sales of $23.017 million, which surpassed the $12.812 million estimate by 79.65% and represented a 78.79% increase over the same period last year.

Beyond the financial beat, Intellia provided encouraging business updates. The company ended 2025 with $605.1 million in cash, cash equivalents and marketable securities, which it expects to fund operations into the second half of 2027. On the pipeline front, the company anticipates topline Phase 3 data for its lonvo-z treatment for hereditary angioedema by mid-2026, with a planned BLA submission in the second half of 2026 and an anticipated U.S. launch in the first half of 2027. Additionally, the FDA lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial for nex-z in ATTR amyloidosis in late January, allowing the company to resume enrollment.